Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INVITAE CORPORATION

(NVTA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Invitae : Ciitizen Announcement Conference Call Presentation

09/07/2021 | 11:52am EST

+

From genetics, health

Acquisition and platform update 09 | 07 | 21

Safe harbor statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding the potential benefits of its pending acquisition of Ciitizen; the expected transaction terms; the company's beliefs regarding its business and business strategy; and the benefits and importance of the company's acquisitions and collaborations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the closing of the pending acquisition of Ciitizen; the ability of the company to achieve the expected benefits of the acquisition; the impact of COVID- 19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the company's ability to continue to grow its business, including internationally; the ability to maintain important customer relationships; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's ability to obtain regulatory approval for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; the applicability of clinical research results to actual outcomes; the success of collaborations; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

© 2021 Invitae Corporation. All Rights Reserved.

2

Single greatest shift in medicine and healthcare

"Modern" medicine

Chemotherapy standard of care Newborn diagnosis after birth

Symptom-based, universally applied

© 2021 Invitae Corporation. All Rights Reserved.

Universal testing for all

Risk information = effective prevention

Earliest detection - disease eradication

Personalized therapy and biomarker driven monitoring

Gene informed healthcare throughout life

3

Invitae's mission and core data tenets

Patients own

Health data

is more

their health

valuable

data

when shared

© 2021 Invitae Corporation. All Rights Reserved.

4

  1. patient-mediatedplatform for data sharing
  1. patient-mediated platform that allows patients to collect and store their medical records, and turns documents into usable, computable and relevant longitudinal data that can be shared with whomever they consent

© 2021 Invitae Corporation. All Rights Reserved.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Invitae Corporation published this content on 07 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 September 2021 15:51:06 UTC.


ę Publicnow 2021
All news about INVITAE CORPORATION
11/09INVITAE CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
11/09Invitae to Seek Acquisition
CI
11/09Raymond James Adjusts Price Target on Invitae to $36 From $38, Maintains Outperform Rat..
MT
11/09Healthcare Stocks Inching Lower in Premarket Tuesday
MT
11/09Wells Fargo Adjusts Invitae's Price Target to $25 From $35, Keeps Equal-Weight Rating
MT
11/08Third Quarter 2021 Financial Results Conference Call Earnings Presentation
PU
11/08Invitae Posts Wider Q3 Loss as Sales Rise, Lowers 2021 Revenue Guidance; Shares Slump 1..
MT
11/08INVITAE : Q3 Earnings Snapshot
AQ
11/08Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third..
PU
11/08Earnings Flash (NVTA) INVITAE CORPORATION Posts Q3 Loss $-0.81, vs. Street Est of $-0.7..
MT
More news
Analyst Recommendations on INVITAE CORPORATION
More recommendations
Financials (USD)
Sales 2021 464 M - -
Net income 2021 -471 M - -
Net Debt 2021 694 M - -
P/E ratio 2021 -6,88x
Yield 2021 -
Capitalization 3 393 M 3 393 M -
EV / Sales 2021 8,81x
EV / Sales 2022 6,58x
Nbr of Employees 2 900
Free-Float 97,4%
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | NVTA | US46185L1035 | MarketScreener
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 14,99 $
Average target price 35,67 $
Spread / Average Target 138%
EPS Revisions
Managers and Directors
Sean Emerson George Chairman, President & Chief Executive Officer
Roxi Wen Chief Financial Officer
Robert Nussbaum Chief Medical Officer
Eric Olivares Chief Science Officer
Layton Wedgeworth Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
INVITAE CORPORATION-64.15%3 393
EXACT SCIENCES CORPORATION-39.19%13 198
GUARDANT HEALTH, INC.-24.22%9 220
BGI GENOMICS CO., LTD.-29.92%5 894
ADAPTIVE BIOTECHNOLOGIES CORPORATION-55.64%3 579
SEEGENE, INC.-33.16%2 910